This document provides a 305-page report on the 2012 global and Chinese synthesis polypeptide drug industry. It includes 250 tables and figures analyzing the industry overview, market conditions, major manufacturers, production and sales, development trends, and investment potential. The report finds that the Chinese market has been growing rapidly in recent years and examines industry opportunities and challenges in China and abroad.
Watch the webinar here: https://bit.ly/2lLquKk
Since 2017 Chinese Health Authority has published new regulation for Co-Review procedure of API, excipient and packaging material. Focusing on the unique regulatory requirement for registration of excipient we will give you an overview about the dossier requirement, ChP compliance and impact for the pharmaceutical industry.
If you want to market your drug into China, are you aware that excipient used in your drug need to be registered and to be compliance wtih Chinese pharmacopoeia? Since 2017 Chinese Health Authority has published new regulation for Co-Review procedure of API, excipient and packaging material. Focusing on the unique regulatory requirement for registration of excipient we will give you an overview about the dossier requirement, ChP compliance and impact for the pharmaceutcal industry.
In this webinar, you will learn:
- Current Chinese regulation for excipient registration
- Chinese pharmacopoeia as standard for the excipients
- Impact of excipient regulation for pharmaceutical industries
This white paper focuses on the 505(b)(2) New Drug Approval (NDA) regulatory pathway, which relies on the public literature of clinical studies and/or the FDA's filing of safety and efficacy data for a previously approved drug.
You may shudder at the thought, but modern enterprise
architecture is slowly but surely returning to the mainframe
fold, at least conceptually, and never more so than with the
idea of virtual desktops – hosted in ‘the cloud’. iStart reviews
the leading alternatives...
by Hayden McCall
http://www.istart.com.au
RAAG-M is the official Marketing Club of Galgotias Business School, Greater Noida. The club aims to provide a platform to the students to nurture their marketing acumen. The club will not only help in bringing the marketer out of the GBS Students but will also bring a new era of marketing in GBS.
Watch the webinar here: https://bit.ly/2lLquKk
Since 2017 Chinese Health Authority has published new regulation for Co-Review procedure of API, excipient and packaging material. Focusing on the unique regulatory requirement for registration of excipient we will give you an overview about the dossier requirement, ChP compliance and impact for the pharmaceutical industry.
If you want to market your drug into China, are you aware that excipient used in your drug need to be registered and to be compliance wtih Chinese pharmacopoeia? Since 2017 Chinese Health Authority has published new regulation for Co-Review procedure of API, excipient and packaging material. Focusing on the unique regulatory requirement for registration of excipient we will give you an overview about the dossier requirement, ChP compliance and impact for the pharmaceutcal industry.
In this webinar, you will learn:
- Current Chinese regulation for excipient registration
- Chinese pharmacopoeia as standard for the excipients
- Impact of excipient regulation for pharmaceutical industries
This white paper focuses on the 505(b)(2) New Drug Approval (NDA) regulatory pathway, which relies on the public literature of clinical studies and/or the FDA's filing of safety and efficacy data for a previously approved drug.
You may shudder at the thought, but modern enterprise
architecture is slowly but surely returning to the mainframe
fold, at least conceptually, and never more so than with the
idea of virtual desktops – hosted in ‘the cloud’. iStart reviews
the leading alternatives...
by Hayden McCall
http://www.istart.com.au
RAAG-M is the official Marketing Club of Galgotias Business School, Greater Noida. The club aims to provide a platform to the students to nurture their marketing acumen. The club will not only help in bringing the marketer out of the GBS Students but will also bring a new era of marketing in GBS.
ReportsnReports – Point of Care Diagnostic Testing World MarketsReportsnReports
Point of care testing (POCT) enables rapid diagnostic tests to be performed while the patient is at the point of care facility where results can be obtained immediately, rather than waiting hours or even days for outside lab results to arrive. Point of care testing covers: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing, rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics, infectious disease testing and cholesterol screening.
Diabetes Therapeutics Market Size in India to 2018 Available on Researchmoz.usAmbikabasa
leading business intelligence provider, has released its latest research Diabetes Therapeutics Market in India to 2018 Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth, which provides insights into the India anti-diabetes market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts. Insights into the diabetes epidemiology, cost of therapy, research and development pipeline and the promising molecules which are anticipated to be launched by 2018 are discussed in the report. The report provides an in-depth analysis type 1 and type 2 diabetes.
Watch the webinar here: https://bit.ly/2lLquKk
Since 2017 Chinese Health Authority has published new regulation for Co-Review procedure of API, excipient and packaging material. Focusing on the unique regulatory requirement for registration of excipient we will give you an overview about the dossier requirement, ChP compliance and impact for the pharmaceutical industry.
If you want to market your drug into China, are you aware that excipient used in your drug need to be registered and to be compliance wtih Chinese pharmacopoeia? Since 2017 Chinese Health Authority has published new regulation for Co-Review procedure of API, excipient and packaging material. Focusing on the unique regulatory requirement for registration of excipient we will give you an overview about the dossier requirement, ChP compliance and impact for the pharmaceutcal industry.
In this webinar, you will learn:
- Current Chinese regulation for excipient registration
- Chinese pharmacopoeia as standard for the excipients
- Impact of excipient regulation for pharmaceutical industries
Diethyl Chlorophosphate Market is highly diverse, with a range of services and specialties, including quantitative and qualitative research, brand research, product testing, customer satisfaction research, and competitive analysis.
Transcript: Selling digital books in 2024: Insights from industry leaders - T...BookNet Canada
The publishing industry has been selling digital audiobooks and ebooks for over a decade and has found its groove. What’s changed? What has stayed the same? Where do we go from here? Join a group of leading sales peers from across the industry for a conversation about the lessons learned since the popularization of digital books, best practices, digital book supply chain management, and more.
Link to video recording: https://bnctechforum.ca/sessions/selling-digital-books-in-2024-insights-from-industry-leaders/
Presented by BookNet Canada on May 28, 2024, with support from the Department of Canadian Heritage.
Connector Corner: Automate dynamic content and events by pushing a buttonDianaGray10
Here is something new! In our next Connector Corner webinar, we will demonstrate how you can use a single workflow to:
Create a campaign using Mailchimp with merge tags/fields
Send an interactive Slack channel message (using buttons)
Have the message received by managers and peers along with a test email for review
But there’s more:
In a second workflow supporting the same use case, you’ll see:
Your campaign sent to target colleagues for approval
If the “Approve” button is clicked, a Jira/Zendesk ticket is created for the marketing design team
But—if the “Reject” button is pushed, colleagues will be alerted via Slack message
Join us to learn more about this new, human-in-the-loop capability, brought to you by Integration Service connectors.
And...
Speakers:
Akshay Agnihotri, Product Manager
Charlie Greenberg, Host
Generating a custom Ruby SDK for your web service or Rails API using Smithyg2nightmarescribd
Have you ever wanted a Ruby client API to communicate with your web service? Smithy is a protocol-agnostic language for defining services and SDKs. Smithy Ruby is an implementation of Smithy that generates a Ruby SDK using a Smithy model. In this talk, we will explore Smithy and Smithy Ruby to learn how to generate custom feature-rich SDKs that can communicate with any web service, such as a Rails JSON API.
Software Delivery At the Speed of AI: Inflectra Invests In AI-Powered QualityInflectra
In this insightful webinar, Inflectra explores how artificial intelligence (AI) is transforming software development and testing. Discover how AI-powered tools are revolutionizing every stage of the software development lifecycle (SDLC), from design and prototyping to testing, deployment, and monitoring.
Learn about:
• The Future of Testing: How AI is shifting testing towards verification, analysis, and higher-level skills, while reducing repetitive tasks.
• Test Automation: How AI-powered test case generation, optimization, and self-healing tests are making testing more efficient and effective.
• Visual Testing: Explore the emerging capabilities of AI in visual testing and how it's set to revolutionize UI verification.
• Inflectra's AI Solutions: See demonstrations of Inflectra's cutting-edge AI tools like the ChatGPT plugin and Azure Open AI platform, designed to streamline your testing process.
Whether you're a developer, tester, or QA professional, this webinar will give you valuable insights into how AI is shaping the future of software delivery.
Elevating Tactical DDD Patterns Through Object CalisthenicsDorra BARTAGUIZ
After immersing yourself in the blue book and its red counterpart, attending DDD-focused conferences, and applying tactical patterns, you're left with a crucial question: How do I ensure my design is effective? Tactical patterns within Domain-Driven Design (DDD) serve as guiding principles for creating clear and manageable domain models. However, achieving success with these patterns requires additional guidance. Interestingly, we've observed that a set of constraints initially designed for training purposes remarkably aligns with effective pattern implementation, offering a more ‘mechanical’ approach. Let's explore together how Object Calisthenics can elevate the design of your tactical DDD patterns, offering concrete help for those venturing into DDD for the first time!
Epistemic Interaction - tuning interfaces to provide information for AI supportAlan Dix
Paper presented at SYNERGY workshop at AVI 2024, Genoa, Italy. 3rd June 2024
https://alandix.com/academic/papers/synergy2024-epistemic/
As machine learning integrates deeper into human-computer interactions, the concept of epistemic interaction emerges, aiming to refine these interactions to enhance system adaptability. This approach encourages minor, intentional adjustments in user behaviour to enrich the data available for system learning. This paper introduces epistemic interaction within the context of human-system communication, illustrating how deliberate interaction design can improve system understanding and adaptation. Through concrete examples, we demonstrate the potential of epistemic interaction to significantly advance human-computer interaction by leveraging intuitive human communication strategies to inform system design and functionality, offering a novel pathway for enriching user-system engagements.
GraphRAG is All You need? LLM & Knowledge GraphGuy Korland
Guy Korland, CEO and Co-founder of FalkorDB, will review two articles on the integration of language models with knowledge graphs.
1. Unifying Large Language Models and Knowledge Graphs: A Roadmap.
https://arxiv.org/abs/2306.08302
2. Microsoft Research's GraphRAG paper and a review paper on various uses of knowledge graphs:
https://www.microsoft.com/en-us/research/blog/graphrag-unlocking-llm-discovery-on-narrative-private-data/
UiPath Test Automation using UiPath Test Suite series, part 3DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 3. In this session, we will cover desktop automation along with UI automation.
Topics covered:
UI automation Introduction,
UI automation Sample
Desktop automation flow
Pradeep Chinnala, Senior Consultant Automation Developer @WonderBotz and UiPath MVP
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
Essentials of Automations: Optimizing FME Workflows with ParametersSafe Software
Are you looking to streamline your workflows and boost your projects’ efficiency? Do you find yourself searching for ways to add flexibility and control over your FME workflows? If so, you’re in the right place.
Join us for an insightful dive into the world of FME parameters, a critical element in optimizing workflow efficiency. This webinar marks the beginning of our three-part “Essentials of Automation” series. This first webinar is designed to equip you with the knowledge and skills to utilize parameters effectively: enhancing the flexibility, maintainability, and user control of your FME projects.
Here’s what you’ll gain:
- Essentials of FME Parameters: Understand the pivotal role of parameters, including Reader/Writer, Transformer, User, and FME Flow categories. Discover how they are the key to unlocking automation and optimization within your workflows.
- Practical Applications in FME Form: Delve into key user parameter types including choice, connections, and file URLs. Allow users to control how a workflow runs, making your workflows more reusable. Learn to import values and deliver the best user experience for your workflows while enhancing accuracy.
- Optimization Strategies in FME Flow: Explore the creation and strategic deployment of parameters in FME Flow, including the use of deployment and geometry parameters, to maximize workflow efficiency.
- Pro Tips for Success: Gain insights on parameterizing connections and leveraging new features like Conditional Visibility for clarity and simplicity.
We’ll wrap up with a glimpse into future webinars, followed by a Q&A session to address your specific questions surrounding this topic.
Don’t miss this opportunity to elevate your FME expertise and drive your projects to new heights of efficiency.
Dev Dives: Train smarter, not harder – active learning and UiPath LLMs for do...UiPathCommunity
💥 Speed, accuracy, and scaling – discover the superpowers of GenAI in action with UiPath Document Understanding and Communications Mining™:
See how to accelerate model training and optimize model performance with active learning
Learn about the latest enhancements to out-of-the-box document processing – with little to no training required
Get an exclusive demo of the new family of UiPath LLMs – GenAI models specialized for processing different types of documents and messages
This is a hands-on session specifically designed for automation developers and AI enthusiasts seeking to enhance their knowledge in leveraging the latest intelligent document processing capabilities offered by UiPath.
Speakers:
👨🏫 Andras Palfi, Senior Product Manager, UiPath
👩🏫 Lenka Dulovicova, Product Program Manager, UiPath
Securing your Kubernetes cluster_ a step-by-step guide to success !KatiaHIMEUR1
Today, after several years of existence, an extremely active community and an ultra-dynamic ecosystem, Kubernetes has established itself as the de facto standard in container orchestration. Thanks to a wide range of managed services, it has never been so easy to set up a ready-to-use Kubernetes cluster.
However, this ease of use means that the subject of security in Kubernetes is often left for later, or even neglected. This exposes companies to significant risks.
In this talk, I'll show you step-by-step how to secure your Kubernetes cluster for greater peace of mind and reliability.
Smart TV Buyer Insights Survey 2024 by 91mobiles.pdf91mobiles
91mobiles recently conducted a Smart TV Buyer Insights Survey in which we asked over 3,000 respondents about the TV they own, aspects they look at on a new TV, and their TV buying preferences.
Neuro-symbolic is not enough, we need neuro-*semantic*Frank van Harmelen
Neuro-symbolic (NeSy) AI is on the rise. However, simply machine learning on just any symbolic structure is not sufficient to really harvest the gains of NeSy. These will only be gained when the symbolic structures have an actual semantics. I give an operational definition of semantics as “predictable inference”.
All of this illustrated with link prediction over knowledge graphs, but the argument is general.
Neuro-symbolic is not enough, we need neuro-*semantic*
2012 deep research report on global and china synthesis polypeptide drug industry
1. 2012 Deep Research Report on Global and
China Synthesis Polypeptide Drug Industry
Pages: 305
Tables and Figures: 250
Published Date : Sep, 2012
Publisher: QYResearch Synthesis Polypeptide Drug Research Center
Contact: Mr. Zhang Dong 86-10-82945717; 86-
13811796901, sales@qyresearch.com
Summary
<2012 Deep Research Report on Global and China Synthesis Polypeptide Drug Industry>
was professional and depth research report on China Synthesis Polypeptide Drug industry.
The report firstly introduced Synthesis Polypeptide Drug basic information included
Synthesis Polypeptide Drug definition classification application industry chain structure
industry overview; international market analysis, China domestic market analysis,
Macroeconomic environment and economic situation analysis and influence, Synthesis
Polypeptide Drug industry policy and plan, Synthesis Polypeptide Drug product
specification, manufacturing process, product cost structure etc. then statistics China key
manufacturers Synthesis Polypeptide Drug capacity production cost price profit production
value gross margin etc details information, at the same time, statistics these
manufacturers Synthesis Polypeptide Drug products customers application capacity market
position company contact information etc company related information, then collect all
these manufacturers data and listed China Synthesis Polypeptide Drug capacity production
capacity market share production market share supply demand shortage import export
consumption etc data statistics, and then introduced China Synthesis Polypeptide Drug
2009-2013 capacity production price cost profit production value gross margin etc
information. And also listed Synthesis Polypeptide Drug upstream raw materials
equipments and Sharp Solarnstream clients alternative products survey analysis and
Synthesis Polypeptide Drug marketing channels industry development trend and proposals.
In the end, this report introduced Synthesis Polypeptide Drug new project SWOT analysis
Investment feasibility analysis investment return analysis and also give related research
conclusions and development trend analysis of
Table of Contents
Chapter One Synthesis Polypeptide Drug Industry Overview 1
1.1 Synthesis Polypeptide Drug Definition 1
1.2 Synthesis Polypeptide Drug Classification and Application 3
1.3 Professional Terms Interpretation 8
2. 1.4 Synthesis Polypeptide Drug Industry Chain Structure 12
1.5 Synthesis Polypeptide Drug Industry Overview 14
Chapter Two Synthesis Polypeptide Drug International and China Market Analysis 16
2.1 Synthesis Polypeptide Drug Industry International Market Analysis 16
2.1.1 Synthesis Polypeptide Drug International Market Development History 16
2.1.2 Synthesis Polypeptide Drug Product and Technology Developments 18
2.1.3 Synthesis Polypeptide Drug Competitive Landscape Analysis 25
2.1.4 Synthesis Polypeptide Drug International Key Countries Development Status 28
2.1.5 Synthesis Polypeptide Drug International Market Development Trend 30
2.2 Synthesis Polypeptide Drug China Market Analysis 33
2.2.1 Synthesis Polypeptide Drug China Market Development History 33
2.2.2 Synthesis Polypeptide Drug Product and Technology Developments 33
2.2.3 Synthesis Polypeptide Drug Competitive Landscape Analysis 35
2.2.4 Synthesis Polypeptide Drug China Key Regions Development Status 37
2.2.5 Synthesis Polypeptide Drug China Market Development Trend 37
2.3 Synthesis Polypeptide Drug International and China Market Comparison Analysis 42
Chapter Three Major Synthesis Polypeptide Drug Analysis 43
3.1 Immunity Regulating Medicine (Allergy Infection and Immune) 43
3.1.1 Glatiramer Injection (Glatiramer Acetate) 43
3.1.2 Thymalfasin for Injection 46
3.1.3 Thymopentin Injection 49
3.1.4 Thymopetidum Injection 53
3.1.5 Summary 55
3.2 Digestive System Drugs (Gastrointestinal Type) 57
3.2.1 Octreotide Acetate Injection 57
3.2.2 Somatostatin for Injection 61
3.3 Bone and Connective Tissue Types (Thyroid hormones Drug) 66
3.3.1 Salmon Calcitonin Injection 67
3.3.2 Elcatonin Injection 70
3.3.4 TerfparaLide Injectlon 72
3.4 Gynecologic or Obstetric Drug 76
3.4.1 Oxytocin Injection 76
3.4.2 Carbetocin Injection 81
3.4.3 Acetate Atosiban Injection 83
3.5 Tumor Drug (hCG) 86
3.5.1 Leuprorelin Acetate Microspheres for Injection 87
3.5.2 Goserelin Acetate 89
3.5.3 Triptorelin Acetate Injection 92
3.5.4 Chorionic Gonadotrophin for Injection 95
3.6 Urinary System Drug (Diabetes Insipidus) 98
3.6.1 Desmopressin Acetate Injection 98
3.6.2 Terlipressin for Injection 101
3. 3.7 Metabolic Drug (Insulin and Other Hypoglycemic Agents) 105
3.7.1 Biosynthetic Glucagon for Injection 105
3.7.2 Exenatide Injection 106
Chapter Four Synthesis Polypeptide Drug Development Environmental Analysis 109
4.1 China's Macroeconomic Environment Analysis 109
4.1.1 China GDP Analysis 109
4.1.2 China CPI Analysis 111
4.2 European Economic Environmental Analysis and Impact 113
4.3 United States Economic Environmental Analysis and Impact 116
4.4 Japan Economic Environmental Analysis and Impact 119
4.5 Global Economic Environmental Analysis and Impact 120
4.5.1 Global Economic Environmental Analysis 120
4.5.2 Global Economic Influence 121
Chapter Five Synthesis Polypeptide Drug Development Policy and Plan 121
5.1 China Government Policy and Development Plan 121
5.2 Industry Policy and Standard 122
5.3 Technical Standard 125
5.4 Technology Replacement and R&D Trends 126
5.5 Hotspots and Influence 127
Chapter Six Synthesis Polypeptide Drug Manufacturing Process and Cost Structure 132
6.1 Synthesis Polypeptide Drug Manufacturing Process Overview 132
6.2 Synthesis Polypeptide Drug Manufacturing Process Analysis 135
6.3 Synthesis Polypeptide Drug Cost Structure Analysis 138
Chapter Seven 2009-2013 Synthesis Polypeptide Drug Productions Supply Sales Demand
Market Status and Forecast 140
7.1 2009-2013 Synthesis Polypeptide Drug Capacity Production Overview 140
7.1.1 2009-2013 Global and China Synthesis Polypeptide Drug Capacity Production 140
7.1.2 2009-2013 Synthesis Polypeptide Drug Production Market Share 146
7.1.3 2009-2013 Synthesis Polypeptide Drug Demand Overview 152
7.1.4 2009-2013 Synthesis Polypeptide Drug Supply Demand and Shortage 152
7.1.5 2009-2013 Synthesis Polypeptide Drug Production Import Export Consumption 153
7.1.6 2009-2013 Synthesis Polypeptide Drug Cost Price Production Value Gross Margin 154
7.2 Different Type Synthesis Polypeptide Drug Sales and Market Scale Analysis 156
7.2.1Thymopentin Injection 156
7.2.2 Thymalfasin Injection 158
7.2.3 Calcitonin Injection 159
7.2.4 Somatostatin for Injection 161
7.2.5Octreotide Acetate Injection 162
7.2.6 Desmopressin Acetate Injection 163
7.3 Synthesis Polypeptide Drug Market Summary 165
4. Chapter Eight Synthesis Polypeptide Drug Key Manufacturers 170
8.1 Novartis 170
8.2 Merck Serono 176
8.3 Ferring Pharmaceuticals 181
8.4 Ipsen PHarma Biotech 188
8.5 Lilly 191
8.6Asahi Kasei 195
8.7 AstraZeneca 199
8.8 SciClone Pharmaceuticals 203
8.9 Takeda 206
8.10 HYBIO Pharmaceutical Co.,Ltd (Shenzhen Stock:300199) 210
8.11 Hainan Zhonghe Pharmaceutical Co.,Ltd 215
8.12 Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd 219
8.13 Beijing Yingu Century Pharmaceutical Co.,Ltd (Beijing Shiqiao Bio-Pharmaceutical
Co.,Ltd) 224
8.14 Hainan Shuangcheng Pharmaceuticals Co.,Ltd 227
8.15 Livzon Pharmaceuticals Co.,Ltd (Livzon:000513) 234
8.16 Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd 238
8.17 Chengdu Tiantaishan Pharmaceutical Co.,Ltd 242
8.18 Beijing Shuanglu Pharmaceutical Co.,Ltd 250
8.19 Yangzijiang Pharmaceutical Co.,Ltd 257
8.20 Changzhou Siyao Pharmaceutical Co.,Ltd 262
Chapter Nine Up and Down Stream Industry Analysis and Influence 267
9.1 Upstream Raw Materials Price Analysis and Influence 267
9.1 Upstream Equipments Market Analysis and Influence 269
9.3 Downstream Demand Analysis and Influence 270
9.4 Industry Policy Analysis and Influence 271
Chapter Ten Synthesis Polypeptide Drug Marketing Channels Analysis 272
10.1 Synthesis Polypeptide Drug Marketing Channels Status 272
10.1.1 Drugs Marketing Channel Developemnt History 272
10.1.1 Prescription Drug Marketing Development Status 273
10.2 Synthesis Polypeptide Drug Marketing Channels Management 274
10.3 Synthesis Polypeptide Drug Marketing Channels Establishment 275
10.4 Synthesis Polypeptide Drug Marketing Channels Development Trend 276
Chapter Eleven Synthesis Polypeptide Drug Industry Development Trend 278
11.1 2012-2016 Synthesis Polypeptide Drug Industry Development Trend 278
11.2 2012-2016 Market Potential Forecast 279
11.3 2012-2016 R&D Trend 280
11.3.1Polypeptide Drug Technical Development Status 280
11.3.2 Polypeptide Drug and Health Care Products Research and Manufacturing
Overview 282
5. 11.3.3 China Polypeptide Drug Development Direction and Prospect 283
11.4 2012-2016 Marketing Channels Change Trend 285
14.4.1 Prescription Drug Marketing Channels Change Trend 285
14.4.2 Prescription Drug Sales Method Five Trend 286
11.5 2012-2016 Competition Pattern Development Trends 288
Chapter Twelve Synthesis Polypeptide Drug Industry Development Proposals 289
12.1 Macroeconomic Development Countermeasures 289
12.2 New Firms Enter Market Strategy 290
12.2.1 New Business Entry Barriers 290
12.2.2 New Corporate Strategy 290
12.3 New Project Investment Proposal 293
12.4 Marketing Channel Strategy Proposals 294
12.5 Competitive Environment Strategy Proposals 296
12.5.1 Competitive Environment Analysis 296
12.5.2 Strategy Proposals 297
Chapter Thirteen Synthesis Polypeptide Drug New Project Investment Feasibility
Analysis 300
13.1 Synthesis Polypeptide Drug Project SWOT Analysis 300
13.2 Synthesis Polypeptide Drug New Project Investment Feasibility Analysis 302
13.2.1 Buildings 302
13.2.2 Investment 303
13.2.3 Project Schedule 303
13.2.4 Project Investment Return and Feasibility Analysis 304
Chapter Fourteen Synthesis Polypeptide Drug Industry Research Conclusions 304
Tables and Figures
Figure Synthesis Polypeptide Process Flow 1
Figure Synthesis Polypeptide Drug Picture-Thymopentin Injection 2
Figure Polypeptide Applications on Health Care Food and Cosmetics Fields 4
Figure Polypeptide Drug Manufacturing Process Method 4
Table Synthesis Polypeptide Drug Classification and Application List 5
Table Synthesis Polypeptide Drug Product Name Use and Annual Sales Revenue (USD)
List 6
Table Listed Polypeptide Drug Name Type Indication 6
Figure Pharmaceutical Industry Value Chain Structure 12
Figure Pharmaceutical Industry Industry Chain Structure 12
Figure Synthesis Polypeptide Drug Industry Chain Structure 13
Figure Synthesis Polypeptide Drug Industrialization System 13
Figure 2000-2011 China Pharmaceutical Industry Sales Revenue and Total Profit (100
Million RMB) and Growth Rate 14
6. Figure 2007-2015 China Synthesis Polypeptide Drug Market Scale (100 Million RMB) and
Growth Rate 15
Figure DNA Transcribed into RNA Diagram 17
Figure RNA Translated into Polypeptide Chains Molecular Diagram 18
Table Polypeptide Drug Three Manufacturing Methods 19
Figure 1984 Chemistry Nobel Prize Winner Robert Bruce Merrifield 20
Figure Polypeptide Solid Phase Synthesis Principle 20
Figure Solid Phase Polypeptide Synthesis 21
Figure United States CS Three Channel Full Automatic Polypeptide Synthetic Instrument 22
Figure Homemade CS136 Model Research Polypeptide Synthetic Instrument 23
Figure Large Scale Liquid Phase Synthesis of Polypeptide 24
Figure Thin Film Evaporator (for perishable goods Concentration) 24
Table Global 2008 Revenue More than 1 Billion Polypeptide Drug Brands List 25
Table Some Listed Polypeptide Drug Indication Classification 26
Figure Listed Polypeptide Drug Indication Classification Market Share 26
Figure 2004-2014 Global Pharmaceutical Sales Revenue (Billion USD) and Growth Rate 30
Figure 2009-2013 International Synthesis Polypeptide Drug Market Scale (100 Million RMB)
and Growth Rate 31
Table 2011 Some Polypeptide Drug Global Sales Revenue (100 Million USD) 31
Figure Each Year Enter Clinical Research Polypeptide Drug Quantity (Piece) 32
Table 17 Emerging Pharmaceutical Market Sizes (Billion USD) 38
Figure 2007-2015 China Pharmaceutical Sales Revenue (100 Million USD) 39
Figure 2009-2015 China Polypeptide Drug Market Scale (100 Million RMB) and Growth
Rate 39
Figure 2009-2015 China Chemical Synthesis Polypeptide Drug Market Scale (100 Million
RMB) and Growth Rate 40
Figure 2009-2015 China Chemical Synthesis Polypeptide Drug Market Scale (100 Million
RMB) and Proportion of China Total Polypeptide Drug Market Scale 41
Figure 2007-2009 China Chemical Synthesis Polypeptide Drug Types Market Share 41
Table Copaxone Neuron Structure Diagram 44
Table Thymalfasin for Injection (Thymalfasin a1) Suppliers List 48
Table 2010 Thymalfasin for Injection Key Products Price (RMB/Piece) List 49
Table Some Thymopentin Injection Suppliers List 51
Table Thymopentin Injection Hospital Purchase Price (RMB/Piece) List 52
Table Thymopetidum Injection Thymopentin Injection Thymalfasin Injection Comparison 56
Table Octreotide Acetate Injection Key Suppliers List 59
Table 2012 Hebei Province Octreotide Acetate Injection Bid Price List 60
Tale Somatostatin for Injection Key Suppliers List 64
Table Somatostatin for Injection Key Products Hospital Average Purchae Price List 64
Table 2012 Hebei Province Somatostatin for Injection Key Suppliers List 65
Table Salmon Calcitonin Injection Suppliers List 69
Table Salmon Calcitonin Injection/Nasal Spray Products Hospital Purchase Price List 69
Table Salmon Calcitonin Injection/Nasal spray Products Retail Price List 70
Table Elcatonin Injection Key Suppliers and Product Selling Price List 72
7. Figure TerfparaLide Injectlon—Forsteo Injection Pen Parts 75
Table 2011Q1 China Some Aproved New Drug Number, Specifications Suppliers and
Indication 76
Table 2012 New Add Key Monitoring Drug Table--TerfparaLide Injectlon 76
Table Oxytocin Injection Key Suppliers List 78
Table Oxytocin Injection Suppliers Products Models List 80
Table Carbetocin Injection Suppliers List 83
Table Acetate Atosiban Injection Supplier Product Specification Price List 85
Table Leuprorelin Acetate Microspheres for Injection Suppliers Product Specification Price
List 88
Table Triptorelin Acetate Injection Suppliers Product Specification Price List 94
Table Chorionic Gonadotrophin for Injection Suppliers Product Specifications List 97
Table 2011 Some Hormone Drugs Independent Pricing and Uniform Pricing Comparison 98
Table Desmopressin Acetate Injection Key Suppliers List 100
Table Desmopressin Acetate Injection Key Suppliers Forms Product Specifications and Bid
Price List 101
Table Terlipressin for Injection Key Brands Manufacturers and Retail Prices 104
Table Biosynthetic Glucagon for Injection Suppliers and Retail Prices List 106
Table Exenatide Suppliers Product Specifications Retail Prices List 109
Figure 2007-2015 China Medical Industry Total Production Value (100 Million RMB) and
Growth Rate 110
Table 2006-2011 China GDP (1000 Million RMB) and Growth Rate 110
Figure 2007-2011 China Medical Industry Total Value and Its Proportion of China Total
GDP 111
Figure 2007-2015 China Individual Medical Expenditure (RMB) 112
Figure 2007-2015 China Health Expenditure Per Capita and National Medical Expenditure
Comparison 112
Figure 2011-2016 China Population Growth and Aging Condition 113
Figure 2006-2011 Europe Several Countries PMI Trend 114
Figure United States CPI and PCE Growth Comparison 117
Figure United States Private Savings Rate Change and Net Export /GDP Proportion Change
Trend 118
Figure United States Public Debt and Deficit Proportion of GDP 119
Figure Japan GDP and CPI Growth Rate Comparison 119
Figure 2009-2011 China Health Capital Investment (100 Million RMB) 122
Table China Pharmaceutical Industry All major Departments and Regulatory Functions 122
Table Pharmaceutical Industry main Laws and Regulations and Policies 125
Table 2009-2012 China Medical and Health System Reform Important Policy 128
Table 2009-2012 China Related Pharmaceutical Product Quality Supervision Policy 129
Table 2008-2012 China Development and Reform Commission Policy on Drug Price
Management Policies 130
Figure PTIPolypeptide Synthetic Instruments Picture 133
Table Synthesis Polypeptide Drug Technology Processes List 133
Figure Polypeptide Pharmaceutical Raw Materials Manufacturing Process Flow 135
8. Figure Freeze Dried Powder Injection Manufacturing Process Flow 136
Figure Small Capacity Injection Manufacturing Process Flow 136
Figure Thymalfasin API Manufacturing Process Flow 137
Figure Thymalfasin Injection Manufacturing Process Flow 138
Figure International Synthesis Polypeptide Drug Cost Structure 139
Table 2009-2011 China Synthesis Polypeptide Drug Cost Structure 139
Table 2009-2013 Global Key Manufacturers Synthesis Polypeptide Drug Capacity and Total
Capacity (10K Piece) List 140
Table 2009-2013 Global Key Manufacturers Synthesis Polypeptide Drug Capacity Market
Share List 140
Table 2009-2013 Global Key Manufacturers Synthesis Polypeptide Drug Production and
Total Production (10K Piece) List 141
Table 2009-2013 Global Key Manufacturers Synthesis Polypeptide Drug Production Market
Share List 141
Table 2009-2013 China Key Manufacturers Synthesis Polypeptide Drug Capacity and Total
Capacity (10K Piece) List 142
Table 2009-2013 China Key Manufacturers Synthesis Polypeptide Drug Capacity Market
Share List 142
Table 2009-2013 China Key Manufacturers Synthesis Polypeptide Drug Production and Total
Production (10K Piece) List 143
Table 2009-2013 China Key Manufacturers Synthesis Polypeptide Drug Production Market
Share List 143
Figure 2009-2013 Global Synthesis Polypeptide Drug Capacity Production (10K Piece) and
Growth Rate 144
Table 2009-2013 Global Synthesis Polypeptide Drug Capacity Utilization Rate List 144
Figure 2009-2013 China Synthesis Polypeptide Drug Capacity Production (10K Piece) and
Growth Rate 145
Table 2009-2013 China Synthesis Polypeptide Drug Capacity Utilization Rate List 145
Table 2009-2013 Key Manufacturers Synthesis Polypeptide Drug China Sales (10K Piece)
Top20 List 146
Table 2009-2013 Key Manufacturers Synthesis Polypeptide Drug China Sales Top20 Market
Share List 147
Table 2010 Key Manufacturers Synthesis Polypeptide Drug China Sales Revenue (100
Million RMB) Top10 List 147
Table 2008-2010 Key Manufacturers Synthesis Polypeptide Drug China Sales Revenue
Top10 Market Share List 148
Figure 2011 Key Manufacturers Synthesis Polypeptide Drug China Sales Market Share 149
Figure 2012 Key Manufacturers Synthesis Polypeptide Drug China Sales TOP20 Market
Share 150
Figure 2011 China Key Manufacturers Synthesis Polypeptide Drug Production Market
Share 151
Figure 2012 China Key Manufacturers Synthesis Polypeptide Drug Production Market
Share 151
Table 2009-2013 Global Synthesis Polypeptide Drug Demand (10K Piece) and Growth
9. Rate 152
Table 2009-2013 China Synthesis Polypeptide Drug Demand (10K Piece) and Growth
Rate 152
Table 2009-2013 China Synthesis Polypeptide Drug Supply Demand and Shortage (10K
Piece) 153
Table 2009-2013 Nine Foreign Enterprises Synthesis Polypeptide Drug China Sales (10K
Piece) List 153
Table 2009-2013 China Synthesis Polypeptide Drug Production Import Export Consumption
(10K Piece) List 154
Table 2007-2009 China Synthesis Polypeptide Drug Price (RMB/Piece) Distribution 154
Table 2009-2011 Hainan Shuangcheng Pharmaceuticals Some Synthesis Polypeptide Drug
Price Cost (RMB/Piece) Gross Margin List 155
Table 2009-2013 China Synthesis Polypeptide DrugProduction (10K Piece) Price Cost Gross
(RMB/Piece) Production Value (10K RMB) Gross Margin List 155
Figure 2011 China Synthesis Polypeptide Drug Market Share by Different Type Drug 156
Figure 2008-2014 China Thymopentin Injection Market Scale (100 Million RMB) and
Growth Rate 157
Figure 2008-2014 China Thymopentin Injection Sales (10K Piece) and Growth Rate 157
Figure 2008-2014 China Thymalfasin Injection Market Scale (100 Million RMB) and Growth
Rate 158
Figure 2008-2014 China Thymalfasin Injection Sales (10K Piece) and Growth Rate 159
Figure 2008-2014 China Calcitonin Injection Market Scale (100 Million RMB) and Growth
Rate 160
Figure 2008-2014 China Calcitonin Injection Sales (10K Piece) and Growth Rate 160
Figure 2008-2014 China Somatostatin for Injection Market Scale (100 Million RMB) and
Growth Rate 161
Figure 2008-2014 China Somatostatin for Injection Sales (10K Piece) and Growth Rate 162
Figure 2008-2014 China Octreotide Acetate Injection Market Scale (100 Million RMB) and
Growth Rate 163
Figure 2008-2014 China Octreotide Acetate Injection Sales (10K Piece) and Growth
Rate 163
Figure 2008-2014 China Desmopressin Acetate Injection Market Scale (100 Million RMB)
and Growth Rate 164
Figure 2008-2014 China Desmopressin Acetate Injection Sales (10K Piece) and Growth
Rate 164
Table 2009-2011 China Chemical Synthesis Polypeptide Drug Injection Distribution List 165
Figure 2010 Global Polypeptide Drug Market Structure by Treatment Class 165
Table Research or Listed Polypeptide Drugs List 166
Figure 1990-2010 China Resident Three Types of Chronic Disease Prevalence (1/100K)
Change Trend 167
Figure 2010 China Synthesis Polypeptide Drug Hospital Terminal Sales Market Share
Distribution 168
Figure 2010 China Synthesis Polypeptide Drug Top10 Manufacturers Sales Revenue (100
Million RMB) 168
10. Figure China Synthesis Polypeptide Drug Prices Distribution 169
Figure Use Me-Too Model Developed Polypeptide Drug List 169
Table Novartis Company Information Table (Products Applications Manufacturing Base
Location Capacity Expansion Plan Market Position Contact Information etc 13 Items) 170
Figure Novartis China Market Sales Synthesis Polypeptide Drug--Octreotide Acetate
Injection 173
Figure Novartis China Market Sales Synthesis Polypeptide Drug--Somatostatin Acetate for
Injection 173
Figure Novartis China Market Sales Synthesis Polypeptide Drug--salmon Calcitonin Nasal
Spray 174
Table 2009-2013 Novartis Synthesis Polypeptide Drug Production (10K Piece) Cost Price
Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List 174
Figure 2009-2013 Novartis Synthesis Polypeptide Drug Capacity Production (10K Piece)
and Growth Rate 175
Table Merck Serono Company Information Table (Products Applications Manufacturing Base
Location Capacity Expansion Plan Market Position Contact Information etc 13 Items) 176
Figure Merck Serono Synthesis Polypeptide Drug--Recombinant Human Follitropin Alfa
Solution for Injection 178
Figure Merck Serono Synthesis Polypeptide Drug--Somatostatin for Injection 179
Figure Merck Serono Synthesis Polypeptide Drug--Gonadorelin for Injection 179
Table 2009-2013 Merck Serono Synthesis Polypeptide Drug Production (10K Piece) Cost
Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List 180
Figure 2009-2013 Merck Serono Synthesis Polypeptide Drug Capacity Production (10K
Piece) and Growth Rate 181
Table Ferring Pharmaceuticals Company Information Table (Products Applications
Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information
etc 13 Items) 182
Figure Ferring Pharmaceuticals China Market Sales Synthesis Polypeptide Drug--
Minirin 183
Figure Ferring Pharmaceuticals China Market Sales Synthesis Polypeptide Drug--
Decapeptyl 184
Figure Ferring Pharmaceuticals China Market Sales Synthesis Polypeptide Drug--
Pentasa 184
Figure Ferring Pharmaceuticals China Market Sales Synthesis Polypeptide Drug--
Glypressin 185
Figure Ferring Pharmaceuticals China Market Sales Synthesis Polypeptide Drug--
Octostim 186
Table 2009-2013 Ferring Pharmaceuticals Synthesis Polypeptide Drug Production (10K
Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List 186
Figure 2009-2013 Ferring Pharmaceuticals Synthesis Polypeptide Drug Capacity Production
(10K Piece) and Growth Rate 188
Table Ipsen PHarma Biotech Company Information Table (Products Applications
Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information
etc 13 Items) 188
11. Figure Ipsen PHarma Biotech Synthesis Polypeptide Drug--Triptorelin Acetate for
Injection 190
Table 2009-2013 Ipsen PHarma Biotech Synthesis Polypeptide Drug Production (10K Piece)
Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List 190
Figure 2009-2013 Ipsen PHarma Biotech Synthesis Polypeptide Drug Capacity Production
(10K Piece) and Growth Rate 191
Table Lilly Company Information Table (Products Applications Manufacturing Base Location
Capacity Expansion Plan Market Position Contact Information etc 13 Items) 192
Figure Lilly Some China Listed Synthesis Polypeptide Drug List 194
Table 2009-2013 Lilly Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross
(RMB/Piece) Production Value (10K RMB) Gross Margin List 194
Figure 2009-2013 Lilly Synthesis Polypeptide Drug Capacity Production (10K Piece) and
Growth Rate 195
Table Asahi Kasei Company Information Table (Products Applications Manufacturing Base
Location Capacity Expansion Plan Market Position Contact Information etc 13 Items) 195
Figure Asahi Kasei Synthesis Polypeptide Drug--Elcatonin Injection 198
Table 2009-2013 Asahi Kasei Synthesis Polypeptide Drug Production (10K Piece) Cost Price
Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List 198
Figure 2009-2013 Asahi Kasei Synthesis Polypeptide Drug Capacity Production (10K Piece)
and Growth Rate 199
Table AstraZeneca Company Information Table (Products Applications Manufacturing Base
Location Capacity Expansion Plan Market Position Contact Information etc 13 Items) 199
Figure AstraZeneca China Selling Synthesis Polypeptide Drug—Goserelin Acetate Slow
Release Implantation Agent 201
Table 2009-2013 Jiangsu AstraZeneca Synthesis Polypeptide Drug Production (10K Piece)
Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List 202
Figure 2009-2013 Jiangsu AstraZeneca Synthesis Polypeptide Drug Capacity Production
(10K Piece) and Growth Rate 203
Table SciClone Pharmaceuticals Company Information Table (Products Applications
Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information
etc 13 Items) 204
Figure SciClone Pharmaceuticals Synthesis Polypeptide Drug-- Thymopetidum α 1
Injection 205
Table 2009-2013 SciClone Pharmaceuticals Synthesis Polypeptide Drug Production (10K
Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List 205
Figure 2009-2013 SciClone Pharmaceuticals Synthesis Polypeptide Drug Capacity
Production (10K Piece) and Growth Rate 206
Table Takeda Company Information Table (Products Applications Manufacturing Base
Location Capacity Expansion Plan Market Position Contact Information etc 13 Items) 206
Figure Takeda--Leuprorelin Acetate Microspheres for Injection 208
Table 2009-2013 Takeda Synthesis Polypeptide Drug Production (10K Piece) Cost Price
Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List 209
Figure 2009-2013 Takeda Synthesis Polypeptide Drug Capacity Production (10K Piece) and
Growth Rate 209
12. Table HYBIO Pharmaceutical Co.,Ltd Company Information Table (Products Applications
Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information
etc 13 Items) 210
Figure 2009-2013 HYBIO Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug 211
Table 2009-2013 HYBIO Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production
(10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin
List 213
Figure 2009-2013 HYBIO Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Capacity
Production (10K Piece) and Growth Rate 215
Table Hainan Zhonghe Pharmaceutical Co.,Ltd Company Information Table (Products
Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact
Information etc 13 Items) 216
Figure Hainan Zhonghe Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug 产品 217
Table 2009-2013 Hainan Zhonghe Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug
Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross
Margin List 217
Figure 2009-2013 Hainan Zhonghe Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug
Capacity Production (10K Piece) and Growth Rate 219
Table Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd Company Information Table
(Products Applications Manufacturing Base Location Capacity Expansion Plan Market
Position Contact Information etc 13 Items) 219
Figure Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd Synthesis Polypeptide Drug—
Thymalfasin Injection 221
Figure Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd Synthesis Polypeptide Drug—
Thymopentin Injection 222
Table 2009-2013 Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd Synthesis
Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value
(10K RMB) Gross Margin List 222
Figure 2009-2013 Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd Synthesis
Polypeptide Drug Capacity Production (10K Piece) and Growth Rate 223
Table Beijing Yingu Century Pharmaceutical Co.,Ltd Company Information Table (Products
Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact
Information etc 13 Items) 224
Figure Beijing Yingu Century Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Salmon
Calcitonin Nasal Spray 225
Figure Beijing Yingu Century Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-
Thymopentin Injection 226
Table 2009-2013 Beijing Yingu Century Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug
Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross
Margin List 226
Figure 2009-2013 Beijing Yingu Century Pharmaceutical Co.,Ltd Synthesis Polypeptide
Drug Capacity Production (10K Piece) and Growth Rate 227
Table Hainan Shuangcheng Pharmaceuticals Co.,Ltd Company Information Table (Products
Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact
13. Information etc 13 Items) 228
Figure Hainan Shuangcheng Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug--
Thymalfasin Injection(基泰) 229
Figure Hainan Shuangcheng Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug—
Somatostatin for Injection 231
Figure Hainan Shuangcheng Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug—
Thymopentin Injection (双成可维) 232
Table 2009-2013 Hainan Shuangcheng Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug
Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross
Margin List 233
Figure 2009-2013 Hainan Shuangcheng Pharmaceuticals Co.,Ltd Synthesis Polypeptide
Drug Capacity Production (10K Piece) and Growth Rate 234
Table Livzon Pharmaceuticals Co.,Ltd Company Information Table (Products Applications
Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information
etc 13 Items) 234
Figure Livzon Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug 236
Table 2009-2013 Livzon Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug Production
(10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin
List 236
Figure 2009-2013 Livzon Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug Capacity
Production (10K Piece) and Growth Rate 238
Table Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd Company Information Table
(Products Applications Manufacturing Base Location Capacity Expansion Plan Market
Position Contact Information etc 13 Items) 239
Figure Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug--
Thymopentin Injection 240
Figure Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug--
Somatostatin for Injection 240
Table 2009-2013 Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd Synthesis
Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value
(10K RMB) Gross Margin List 241
Figure 2009-2013 Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd Synthesis
Polypeptide Drug Capacity Production (10K Piece) and Growth Rate 242
Table Chengdu Tiantaishan Pharmaceutical Co.,Ltd Company Information Table (Products
Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact
Information etc 13 Items) 242
Figure Chengdu Tiantaishan Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug—
Somatostatin for Injection 244
Figure Chengdu Tiantaishan Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug—
Thymopentin Injection 246
Figure Chengdu Tiantaishan Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug—
Octreotide Acetate Injection 247
Table 2009-2013 Chengdu Tiantaishan Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug
Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross
14. Margin List 248
Figure 2009-2013 Chengdu Tiantaishan Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug
Capacity Production (10K Piece) and Growth Rate 249
Table Beijing Shuanglu Pharmaceutical Co.,Ltd Company Information Table (Products
Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact
Information etc 13 Items) 250
Figure Beijing Shuanglu Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Thymopentin
Injection 251
Figure Beijing Shuanglu Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Salmon
Calcitonin Injection 252
Table Beijing Shuanglu Pharmaceutical Co.,Ltd Thymopentin Injection Price List 253
Table 2009-2013 Beijing Shuanglu Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug
Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross
Margin List 256
Figure 2009-2013 Beijing Shuanglu Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug
Capacity Production (10K Piece) and Growth Rate 257
Table Yangzijiang Pharmaceutical Co.,Ltd Company Information Table (Products
Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact
Information etc 13 Items) 257
Figure Yangzijiang Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Somatostatin for
Injection 259
Figure Yangzijiang Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Thymopentin
Injection 260
Table 2009-2013 Yangzijiang Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug
Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross
Margin List 260
Figure 2009-2013 Yangzijiang Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Capacity
Production (10K Piece) and Growth Rate 261
Table Changzhou Siyao Pharmaceutical Co.,Ltd Company Information Table (Products
Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact
Information etc 13 Items) 262
Figure Changzhou Siyao Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug List 264
Table Changzhou Siyao Pharmaceutical Co.,Ltd Chemical Pharmaceutical Raw Materials
List 264
Table Changzhou Siyao Pharmaceutical Co.,Ltd Chemical Raw Materials Intermediates
List 265
Table 2009-2013 Changzhou Siyao Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug
Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross
Margin List 266
Figure 2009-2013 Changzhou Siyao Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug
Capacity Production (10K Piece) and Growth Rate 266
Table Synthesis Polypeptide Drug Project Key Equipments and Price (10K RMB) 269
Table Synthesis Polypeptide Drug Project Equipments List and Price (10K RMB) 270
Table Drugs Manufacturing Enterprise Specialized Academic Promotion Organization
15. Frame 276
Figure Synthesis Polypeptide Drug Industry Entry Barriers List 293
Table 2012 China Synthesis Polypeptide Drug New Project SWOT Analysis 300
Table 2012 China Synthesis Polypeptide Drug New Project Buildings List 302
Table 2012 China Synthesis Polypeptide Drug New Project Investments (10K RMB) List 303
Table Synthesis Polypeptide Drug New Project Investment Return and Feasibility
Analysis 304